UNSPSC 51362407: Triclofos sodium

This classification denotes a sedative and hypnotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9F90KA5Q8U. European Medicines Agency schedules Triclofos sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15606MIG. Triclofos sodium generally arises in the molecular formula C2H3CL3O4P.NA. The term 'triclofos sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule triclofos sodium under HS 29199090 and SITC 51631.

As of Q4 2014, TRICLOFOS SODIUM remains US FDA's Preferred Term for this commodity. Triclofos sodium bears US NLM identifiers UMLS ID C0355022 and NCI Concept Code C66630. SMILES: C(C(CL)(CL)CL)OP(=O)(O)[O-].[NA+].

UNSPSC 51362407 Triclofos sodium is a Commodity-tier code nominally covering a specific pharmaceutical ingredient, but the recent state and local opportunities posted under it bear no relationship to triclofos sodium itself. The three most recent solicitations address naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution — none of which involve triclofos sodium as a product or ingredient. This mismatch suggests either a cataloging error in the state and local procurement system or that the code is being used as a catch-all placeholder for pharmaceutical procurement activity more broadly. The code shows limited decision relevance for vendors specializing in triclofos sodium or other active pharmaceutical ingredients; firms pursuing state and local pharmaceutical business should monitor higher-level pharmaceutical family and class codes rather than rely on this commodity designation.

The three opportunities posted under the code in the past six months span Florida county government, a multistate cooperative purchasing alliance, and a state health agency. Seminole County, Florida issued an IFB (No. IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP (No. S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products available through three authorized wholesalers, with awards effective July 1, 2026. The Texas Health and Human Services Commission issued an RFI (No. HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription capabilities for a Therapeutic Pharmacy Initiative. Geographic activity is scattered across Florida, Texas, and the upper Midwest; the multistate cooperative vehicle suggests broader regional reach among participating state and local members, but no concentration in any single jurisdiction or region is evident from the source.